^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
INCB62079
i
Other names: INCB62079, INCB 62079, INCB062079, INCB-062079, INCB-62079
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Incyte
Drug class:
FGFR4 inhibitor
Related drugs:
1year
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. (PubMed, Target Oncol)
With C4 cut-off and prophylactic bile acid sequestrant implementation, INCB062079 demonstrated a manageable safety profile and evidence of target inhibition. In view of the rarity of FGF19/FGFR4 alterations and slow patient accrual, the study was terminated before establishing an MTD.
P1 data • Clinical Trial,Phase I • Journal • Metastases
|
FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4)
|
INCB62079
Share via
